Search

Your search keyword '"Bae, Junhwan"' showing total 12 results
Start Over Author "Bae, Junhwan"
12 results on '"Bae, Junhwan"'

5. 5-Fluorouracil crystal-incorporated, pH-responsive, and release-modulating PLGA/Eudragit FS hybrid microparticles for local colorectal cancer-targeted chemotherapy

Author

Lee, Juho, primary, Bae, Junhwan, additional, Kwak, Dongmin, additional, Kim, Hyunwoo, additional, Kim, Jihyun, additional, Phyu Hlaing, Shwe, additional, Saparbayeva, Aruzhan, additional, Hee Lee, Eun, additional, Yoon, In-Soo, additional, Kim, Min-Soo, additional, Ryong Moon, Hyung, additional, and Yoo, Jin-Wook, additional

Published
2023
Full Text
View/download PDF

7. Colon-targeted delivery of cyclosporine A using dual-functional Eudragit® FS30D/PLGA nanoparticles ameliorates murine experimental colitis

Author

Naeem, Muhammad, Bae, Junhwan, Oshi, Murtada A, Kim, Min-Soo, Moon, Hyung Ryong, Lee, Bok Luel, Im, Eunok, Jung, Yunjin, and Yoo, Jin-Wook

Subjects
Colon, colon-targeted nanoparticles, Administration, Oral, Drug Delivery Systems, Polylactic Acid-Polyglycolic Acid Copolymer, Animals, Methylmethacrylates, Lactic Acid, Particle Size, Original Research, ulcerative colitis, Peroxidase, Drug Carriers, Mice, Inbred ICR, Macrophages, Body Weight, Hydrogen-Ion Concentration, Colitis, sustained and pH-sensitive release, Drug Liberation, Treatment Outcome, Cyclosporine, Cytokines, Nanoparticles, Inflammation Mediators, cyclosporine A, Immunosuppressive Agents, Polyglycolic Acid
Abstract

Background Colon-targeted oral nanoparticles (NPs) have emerged as an ideal, safe, and effective therapy for ulcerative colitis (UC) owing to their ability to selectively accumulate in inflamed colonic mucosa. Cyclosporine A (CSA), an immunosuppressive agent, has long been used as rescue therapy in severe steroid-refractory UC. In this study, we developed CSA-loaded dual-functional polymeric NPs composed of Eudragit® FS30D as a pH-sensitive polymer for targeted delivery to the inflamed colon, and poly(lactic-co-glycolic acid) (PLGA) as a sustained-release polymer. Methods CSA-loaded Eudragit FS30D nanoparticles (ENPs), PLGA nanoparticles (PNPs), and Eudragit FS30D/PLGA nanoparticles (E/PNPs) were prepared using the oil-in-water emulsion method. Scanning electron microscope images and zeta size data showed successful preparation of CSA-loaded NPs. Results PNPs exhibited a burst drug release of >60% at pH 1.2 (stomach pH) in 0.5 h, which can lead to unwanted systemic absorption and side effects. ENPs effectively inhibited the burst drug release at pH 1.2 and 6.8 (proximal small intestine pH); however, nearly 100% of the CSA in ENPs was released rapidly at pH 7.4 (ileum–colon pH) owing to complete NP dissolution. In contrast to single-functional PNPs and ENPs, the dual-functional E/PNPs minimized burst drug release (only 18%) at pH 1.2 and 6.8, and generated a sustained release at pH 7.4 thereafter. Importantly, in distribution studies in the gastrointestinal tracts of mice, E/PNPs significantly improved CSA distribution to the colon compared with PNPs or ENPs. In a mouse model of colitis, E/PNP treatment improved weight loss and colon length, and decreased rectal bleeding, spleen weight, histological scoring, myeloperoxidase activity, macrophage infiltration, and expression of proinflammatory cytokines compared with PNPs or ENPs. Conclusion Overall, this work confirms the benefits of CSA-loaded E/PNPs for efficiently delivering CSA to the colon, suggesting their potential for UC therapy.

Published
2018

9. Colon-targeted delivery of cyclosporine A using dual-functional Eudragit® FS30D/PLGA nanoparticles ameliorates murine experimental colitis

Author

Naeem,Muhammad, Bae,Junhwan, A. Oshi,Murtada, Kim,Min-Soo, Moon,Hyung Ryong, Lee,Bok Luel, Im,Eunok, Jung,Yunjin, Yoo,Jin-Wook, Naeem,Muhammad, Bae,Junhwan, A. Oshi,Murtada, Kim,Min-Soo, Moon,Hyung Ryong, Lee,Bok Luel, Im,Eunok, Jung,Yunjin, and Yoo,Jin-Wook

Abstract

Muhammad Naeem,* Junhwan Bae,* Murtada A Oshi, Min-Soo Kim, Hyung Ryong Moon, Bok Luel Lee, Eunok Im, Yunjin Jung, Jin-Wook Yoo College of Pharmacy, Pusan National University, Busan, Republic of Korea *These authors contributed equally to this work Background: Colon-targeted oral nanoparticles (NPs) have emerged as an ideal, safe, and effective therapy for ulcerative colitis (UC) owing to their ability to selectively accumulate in inflamed colonic mucosa. Cyclosporine A (CSA), an immunosuppressive agent, has long been used as rescue therapy in severe steroid-refractory UC. In this study, we developed CSA-loaded dual-functional polymeric NPs composed of Eudragit® FS30D as a pH-sensitive polymer for targeted delivery to the inflamed colon, and poly(lactic-co-glycolic acid) (PLGA) as a sustained-release polymer.Methods: CSA-loaded Eudragit FS30D nanoparticles (ENPs), PLGA nanoparticles (PNPs), and Eudragit FS30D/PLGA nanoparticles (E/PNPs) were prepared using the oil-in-water emulsion method. Scanning electron microscope images and zeta size data showed successful preparation of CSA-loaded NPs.Results: PNPs exhibited a burst drug release of >60% at pH 1.2 (stomach pH) in 0.5 h, which can lead to unwanted systemic absorption and side effects. ENPs effectively inhibited the burst drug release at pH 1.2 and 6.8 (proximal small intestine pH); however, nearly 100% of the CSA in ENPs was released rapidly at pH 7.4 (ileum–colon pH) owing to complete NP dissolution. In contrast to single-functional PNPs and ENPs, the dual-functional E/PNPs minimized burst drug release (only 18%) at pH 1.2 and 6.8, and generated a sustained release at pH 7.4 thereafter. Importantly, in distribution studies in the gastrointestinal tracts of mice, E/PNPs significantly improved CSA distribution to the colon compared with PNPs or ENPs. In a mouse model of colitis, E/PNP treatment improved weight loss and colon length, and decreased rectal bleeding, spleen weight, h

Published
2018

12. Colon-targeted delivery of cyclosporine A using dual-functional Eudragit ® FS30D/PLGA nanoparticles ameliorates murine experimental colitis.

Author

Naeem M, Bae J, Oshi MA, Kim MS, Moon HR, Lee BL, Im E, Jung Y, and Yoo JW

Subjects
Administration, Oral, Animals, Body Weight, Colitis chemically induced, Colitis pathology, Cytokines metabolism, Drug Carriers administration & dosage, Drug Liberation, Hydrogen-Ion Concentration, Immunosuppressive Agents therapeutic use, Inflammation Mediators metabolism, Macrophages drug effects, Macrophages pathology, Mice, Inbred ICR, Nanoparticles administration & dosage, Nanoparticles ultrastructure, Particle Size, Peroxidase metabolism, Polylactic Acid-Polyglycolic Acid Copolymer, Treatment Outcome, Colitis drug therapy, Colon pathology, Cyclosporine administration & dosage, Cyclosporine therapeutic use, Drug Delivery Systems, Lactic Acid chemistry, Methylmethacrylates chemistry, Nanoparticles chemistry, Polyglycolic Acid chemistry
Abstract

Background: Colon-targeted oral nanoparticles (NPs) have emerged as an ideal, safe, and effective therapy for ulcerative colitis (UC) owing to their ability to selectively accumulate in inflamed colonic mucosa. Cyclosporine A (CSA), an immunosuppressive agent, has long been used as rescue therapy in severe steroid-refractory UC. In this study, we developed CSA-loaded dual-functional polymeric NPs composed of Eudragit ® FS30D as a pH-sensitive polymer for targeted delivery to the inflamed colon, and poly(lactic-co-glycolic acid) (PLGA) as a sustained-release polymer., Methods: CSA-loaded Eudragit FS30D nanoparticles (ENPs), PLGA nanoparticles (PNPs), and Eudragit FS30D/PLGA nanoparticles (E/PNPs) were prepared using the oil-in-water emulsion method. Scanning electron microscope images and zeta size data showed successful preparation of CSA-loaded NPs., Results: PNPs exhibited a burst drug release of >60% at pH 1.2 (stomach pH) in 0.5 h, which can lead to unwanted systemic absorption and side effects. ENPs effectively inhibited the burst drug release at pH 1.2 and 6.8 (proximal small intestine pH); however, nearly 100% of the CSA in ENPs was released rapidly at pH 7.4 (ileum-colon pH) owing to complete NP dissolution. In contrast to single-functional PNPs and ENPs, the dual-functional E/PNPs minimized burst drug release (only 18%) at pH 1.2 and 6.8, and generated a sustained release at pH 7.4 thereafter. Importantly, in distribution studies in the gastrointestinal tracts of mice, E/PNPs significantly improved CSA distribution to the colon compared with PNPs or ENPs. In a mouse model of colitis, E/PNP treatment improved weight loss and colon length, and decreased rectal bleeding, spleen weight, histological scoring, myeloperoxidase activity, macrophage infiltration, and expression of proinflammatory cytokines compared with PNPs or ENPs., Conclusion: Overall, this work confirms the benefits of CSA-loaded E/PNPs for efficiently delivering CSA to the colon, suggesting their potential for UC therapy., Competing Interests: Disclosure The authors report no conflicts of interest in this work.

Published
2018
Full Text
View/download PDF

Catalog

Books, media, physical & digital resources
See catalog results